Vanguard Group
EWTX icon

Vanguard Group’s Edgewise Therapeutics EWTX Stock Holding History

Vanguard Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$121M Buy
4,871,624
+67,683
+1% +$1.36M ﹤0.01% 1793
2025
Q3 		$77.9M Sell
4,803,941
-37,559
-0.8% -$533K ﹤0.01% 1962
2025
Q2 		$63.5M Buy
4,841,500
+547,096
+13% +$7.89M ﹤0.01% 2023
2025
Q1 		$94.5M Sell
4,294,404
-172,445
-4% -$4.52M ﹤0.01% 1824
2024
Q4 		$119M Sell
4,466,849
-49,214
-1% -$1.57M ﹤0.01% 1792
2024
Q3 		$121M Buy
4,516,063
+7,897
+0.2% +$157K ﹤0.01% 1785
2024
Q2 		$81.2M Buy
4,508,166
+490,733
+12% +$8.56M ﹤0.01% 1936
2024
Q1 		$73.3M Buy
4,017,433
+1,892,053
+89% +$30.1M ﹤0.01% 2014
2023
Q4 		$23.3M Buy
2,125,380
+60,959
+3% +$428K ﹤0.01% 2525
2023
Q3 		$11.8M Buy
2,064,421
+32,462
+2% +$221K ﹤0.01% 2783
2023
Q2 		$15.7M Buy
2,031,959
+26,134
+1% +$220K ﹤0.01% 2695
2023
Q1 		$13.4M Buy
2,005,825
+22,821
+1% +$212K ﹤0.01% 2787
2022
Q4 		$17.7M Buy
1,983,004
+231,159
+13% +$2.17M ﹤0.01% 2676
2022
Q3 		$17.2M Buy
1,751,845
+525,277
+43% +$5.31M ﹤0.01% 2699
2022
Q2 		$9.76M Buy
1,226,568
+15,475
+1% +$117K ﹤0.01% 3001
2022
Q1 		$11.7M Buy
1,211,093
+11,693
+1% +$151K ﹤0.01% 3067
2021
Q4 		$18.3M Buy
1,199,400
+611,879
+104% +$11M ﹤0.01% 2886
2021
Q3 		$9.75M Buy
587,521
+4,658
+0.8% +$84.2K ﹤0.01% 3258
2021
Q2 		$12.4M Buy
582,863
+462,863
+386% +$12.7M ﹤0.01% 3097
2021
Q1 		$3.9M Buy
+120,000
New +$3.89M ﹤0.01% 3656

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group's EWTX Position: Q4 2025 in Review

Vanguard Group increased its Edgewise Therapeutics (EWTX) stake by 1.4% in Q4 2025, buying an estimated $1.36M and bringing the position to 4,871,624 shares worth $121M. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

Vanguard Group first reported a position in EWTX in Q1 2021 and has held it in 20 quarters since. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • Vanguard Group held 4,871,624 shares of Edgewise Therapeutics worth $121M as of Q4 2025.
  • Vanguard Group bought 67,683 Edgewise Therapeutics shares in Q4 2025, an estimated $1.36M.
  • Edgewise Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1793 holding.
  • Vanguard Group first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.